Literature DB >> 14675736

Cytochrome c oxidase is decreased in Alzheimer's disease platelets.

Sandra Morais Cardoso1, M Teresa Proença, Sancha Santos, Isabel Santana, Catarina R Oliveira.   

Abstract

Cytochrome c oxidase (COX) activity reportedly is reduced in Alzheimer's disease (AD) brain and platelets. The reasons for the defect in either tissue are unknown, but its presence in a non-degenerating tissue suggests it is not simply a consequence of neurodegeneration. We now offer confirmation of the AD platelet COX defect. Compared to age-matched controls, in mitochondria isolated from AD platelets there was a 15% decrease in COX activity despite the fact that COX subunits were present at normal levels. Platelet ATP levels were diminished in AD (from 11.33 +/- 0.52 to 9.11 +/- 0.72 nmol/mg), while reactive oxygen species (ROS) were increased (from 97.03 +/- 25.9 to 338.3 +/- 100 K/mg). Platelet membrane fluidity, Vitamin E, and cholesterol content were similar between groups. We conclude that COX catalytic activity is indeed diminished in AD platelet mitochondria, does not result from altered membrane fluidity, and is associated with ROS overproduction and ATP under-production.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14675736     DOI: 10.1016/s0197-4580(03)00033-2

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  99 in total

Review 1.  Somatic mutations in aging, cancer and neurodegeneration.

Authors:  Scott R Kennedy; Lawrence A Loeb; Alan J Herr
Journal:  Mech Ageing Dev       Date:  2011-11-03       Impact factor: 5.432

2.  Intermittent hypoxia conditioning protects mitochondrial cytochrome c oxidase of rat cerebellum from ethanol withdrawal stress.

Authors:  Xiaohua Ju; Robert T Mallet; H Fred Downey; Daniel B Metzger; Marianna E Jung
Journal:  J Appl Physiol (1985)       Date:  2012-03-08

Review 3.  Role of mitochondrial homeostasis and dynamics in Alzheimer's disease.

Authors:  J Eva Selfridge; Lezi E; Jianghua Lu; Russell H Swerdlow
Journal:  Neurobiol Dis       Date:  2012-01-10       Impact factor: 5.996

Review 4.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

5.  Platelet mitochondrial complex I and I+III activities do not correlate with cerebral mitochondrial oxidative metabolism.

Authors:  William J Powers; Richard H Haas; Thuy Le; Tom O Videen; Joanne Markham; Joel S Perlmutter
Journal:  J Cereb Blood Flow Metab       Date:  2010-10-20       Impact factor: 6.200

6.  Effects of edaravone on amyloid-β precursor protein processing in SY5Y-APP695 cells.

Authors:  Yue-E Shen; Yan Wang; Gui-Chun Yu; Chao Liu; Zhen-Yu Zhang; Li-Ming Zhang
Journal:  Neurotox Res       Date:  2013-01-17       Impact factor: 3.911

7.  Effects of Al Exposure on Mitochondrial Dynamics in Rat Hippocampus.

Authors:  Jisheng Nie; Shengjie Lv; Xueying Fu; Qiao Niu
Journal:  Neurotox Res       Date:  2019-05-04       Impact factor: 3.911

Review 8.  Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Sandra M Cardoso; Russell H Swerdlow
Journal:  Adv Pharmacol       Date:  2012

Review 9.  Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease.

Authors:  Jia Yao; Roberta Diaz Brinton
Journal:  Adv Pharmacol       Date:  2012

10.  Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication.

Authors:  Pinar E Coskun; M Flint Beal; Douglas C Wallace
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.